Alternative to methylphenidate; possible benefit from osteoporosis drug.(PSYCHOPHARMACOLOGY)

Publication: Behavioral Healthcare Tomorrow

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2005 Manisses Communications Group, Inc.

Reboxetine May Prove Effective Among Methylphenidate-Resistant

A small open-label study has indicated that a once-daily dose of the medication reboxetine may reduce symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents for whom the drug methylphenidate has not worked. The study looked at 31 Israeli children ages 8 to 18, all of whom had failed on a previous trial of methylphenidate or had experienced adverse effects that resulted in discontinuation of the medication. Subjects received 4 mg of reboxetine each morning, and were maintained on this dose for a six-week study period. Results showed a significant decrease in a variety of ADHD symptoms as measured by several scales.

For example, significant decreases in both inattention and hyperactivity/impulsivity symptoms were seen after two weeks of reboxetine...

Read the full article for free courtesy of your local library.